Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal (MDGL)
:MDGL
RESEARCH TOOLSreports
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$189.00 - $368.29
Previous CloseN/A
Volume47.78K
Average Volume (3M)424.84K
Market Cap
$7.35B
Enterprise Value$3.73B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Feb 26, 2025EPS Estimate
-3.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.07
Shares Outstanding21,810,408
10 Day Avg. Volume343,667
30 Day Avg. Volume424,840
Standard Deviation0.44
R-Squared0.00206
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)95.75
Price to Cash Flow (P/CF)-27.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.08K
Enterprise Value/Ebitda-7.42
Forecast
1Y Price Target
$375.77Price Target Upside10.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Market PerformanceMDGL's Rezdiffra net sequential sales growth is at least 61% over the previous quarter, indicating strong market performance.
Market PotentialRezdiffra has the potential to penetrate further in the MASH market, which is large with ample room for different products.
Revenue And SalesRezdiffra revenues of $100-103mn beat sellside consensus of $91.5mn and the higher buyside expectations.
Bears Say
Competitive RisksThere could eventually be long-term competitive risk for Madrigal should Rezdiffra launch in the severe cirrhotic population.
Regulatory RisksKey risks to the stock rating and price target include potential failure to obtain FDA or EMA approvals and possible clinical trial failures.
Sales ExpectationsSales were generally in line but didn't beat buyside expectations, leading the stock to give up some of the gains.
---
Ownership Overview
19.56% Insiders
27.43% Mutual Funds
0.07% Other Institutional Investors
38.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MDGL FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was $189.00 and its highest was $368.29 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $7.35B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Feb 26, 2025 which is in 6 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on Oct 31, 2024. The company reported -$4.92 earnings per share for the quarter, beating the consensus estimate of -$6.748 by $1.828.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -3.92.
How many shares outstanding does Madrigal have?
Madrigal has 21,810,408 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$4.92 in its last earnings report, beating expectations of -$6.748. Following the earnings report the stock price went up 20.104%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in MDGL
---
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$375.77 (10.56% Upside)
$375.77 (10.56% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $4.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.78%
12-Months-Change
Fundamentals
Return on Equity
-129.76%
Trailing 12-Months
Asset Growth
351.02%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
MDGL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong and promising launch of Rezdiffra with significant achievements in sales, coverage, and prescriber penetration. However, increased operational expenses and future uncertainties in gross-to-net adjustments present challenges. Overall, the sentiment is optimistic with a cautious outlook on future financial dynamics.Read More>---
MDGL Stock 12 Month Forecast
Average Price Target
$375.77
▲(10.56% Upside)
Technical Analysis
Altimmune
―
Galectin Therapeutics
―
Galmed Pharmaceuticals
―
Viking Therapeutics
―
Akero Therapeutics
―
Best Analysts Covering MDGL
1 Year
1 Year Success Rate
14/18 ratings generated profit
1 Year Average Return
+33.74%
reiterated a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +33.74% per trade.
---